Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexchlorpheniramine + pseudoephedrine + guaifenesin is a fixed-dose combination medication used to relieve symptoms associated with the common cold, allergies (such as hay fever), sinusitis, and other upper respiratory tract conditions. It contains three active ingredients: - Dexchlorpheniramine is an antihistamine that blocks histamine H1 receptors to reduce symptoms like sneezing, itching, watery eyes, and runny nose. - Pseudoephedrine is a sympathomimetic decongestant that works by constricting blood vessels in the nasal passages to decrease swelling and congestion. - Guaifenesin is an expectorant that thins and loosens mucus in the airways to facilitate its removal through coughing. This combination targets multiple pathways involved in respiratory symptoms—histaminergic (allergy), adrenergic (congestion), and mucolytic/expectorant mechanisms—to provide broad symptomatic relief. It does not treat underlying infections or shorten illness duration[1][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dexchlorpheniramine + Pseudoephedrine + Guaifenesin.